Nektar (NKTR) Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's (MRK) KEYTRUDA in Patients with SCCHN
Go back to Nektar (NKTR) Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's (MRK) KEYTRUDA in Patients with SCCHN| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 1.32 -0.06 (4.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.38 | 52 Week High | $19.98 | |||
| Open | $1.36 | 52 Week Low | $10.52 | |||
| Day High | $1.37 | P/E | N/A | |||
| Day Low | $1.32 | EPS | $-1.45 | |||
| Volume | 313,961 | |||||
